Paper of the Month - October, 2012

0 rating

Whole-genome analysis informs breast cancer response to aromatase inhibition.

Ellis MJ, Ding L, Shen D et al.
Although estrogen receptor-α (ER-α)-positive breast cancers have the best prognosis of all the breast cancer subsets, there is a large amount of heterogeneity within ER-α-positive tumors. Indeed, classifying these tumors into luminal A and luminal B by expression array analysis has shown that luminal B tumors have a poorer prognosis than luminal A-type tumors.


READER POLL

Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?






Powered by NetPolls

WEB LINKS

SUBMIT AN ARTICLE